What 11 Analyst Ratings Have To Say About NovoCure
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 11 analysts have published their opinion on NovoCure (NASDAQ:NVCR) stock. The average price target is $64.36, implying an upside from the current price of $20.475. This represents a 21.03% decrease from the previous average price target of $81.50. The ratings are divided into 3 bullish, 4 somewhat bullish, and 4 indifferent.
August 29, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have given a bullish to neutral outlook on NovoCure's stock with an average price target of $64.36, which is significantly higher than the current price of $20.475.
The average price target given by the analysts is significantly higher than the current price, indicating a bullish outlook. However, the fact that there are also indifferent ratings suggests some uncertainty, which could lead to volatility in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100